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Abstract: Rosuvastatin is a synthetic statin that represents an advance in the pharmacologic 
and clinical properties of statins. Relative to other statins, rosuvastatin possesses a greater 
number of binding interactions with HMG-CoA reductase and has a high afﬁ  nity for the active 
site of the enzyme. As with other statins, serious adverse effects with rosuvastatin therapy are 
uncommon and primarily involve effects on the liver and skeletal muscle. The risk increases 
with increasing dosages and coadministration with other drugs interacting with the same 
metabolic pathway. The degree of LDL reduction is important to achieve the treatment goals 
suggested by international guidelines. Among the most potent statins, rosuvastatin is capable 
of getting the majority of patients to their LDL cholesterol goals. In addition, rosuvastatin has 
been found effective in reducing small-dense LDL, C-reactive protein and in increasing HDL 
cholesterol levels. Controlled clinical trials using vascular end-points have been performed. In 
particular, a study demonstrated that rosuvastatin therapy could slow progression and/or cause 
regression of carotid intima-media thickness over 2 years in middle-aged individuals with a 
low Framingham risk score (FRS) and mild to moderate subclinical atherosclerosis. A primary 
prevention study (JUPITER) was stopped before the programmed end of the study, because 
of excess beneﬁ  t for high-risk individuals receiving rosuvastatin treatment. It is suggested that 
pronounced LDL reduction, in association with signiﬁ  cant HDL cholesterol increase, are the 
bases of a marked preventive action of rosuvastatin. The results from JUPITER support the use 
of rosuvastatin for primary cardiovascular prevention, in overweight men and women, with near 
to normal LDL cholesterol and high CRP. There is now evidence of beneﬁ  t from rosuvastatin 
treatment for a wide segment of the general population at intermediate cardiovascular risk. In 
absolute numbers, this segment represents the main source of cardiovascular events: on the 
basis of JUPITER results, it is expected that treatment target and potential candidates to statin 
therapy will be revaluated and redeﬁ  ned.
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Rosuvastatin: a new drug
During the last 20 years evidence has accumulated showing dramatic reduction in 
cardiovascular risk using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 
(“statins”) to lower levels of low-density lipoprotein (LDL) cholesterol. In general, 
a 21% reduction in the risk of major cardiovascular events is associated with every 
1 mmol/L (39 mg/dL) decrease in LDL cholesterol.1 However, despite this therapeutic 
success, the residual risk of major cardiovascular events remains high. This is the basis 
of scientiﬁ  c and public health interest in new drugs and intervention strategies aimed 
at reducing the still high cardiovascular risk in the population.
Rosuvastatin is a synthetic statin that represents an advance in the pharmacologic 
and clinical properties of statins. Relative to other statins, rosuvastatin possesses a 
greater number of binding interactions with HMG-CoA reductase and has a high afﬁ  nity 
for the active site of the enzyme. Rosuvastatin is relatively hydrophilic and is selectively Vascular Health and Risk Management 2009:5 344
Rubba et al
taken up by, and active in, hepatic cells. Rosuvastatin has 
the longest terminal half-life among statins and is only 
minimally metabolized by the cytochrome P450 (CYP 450) 
enzyme system, with no signiﬁ  cant involvement of the 3A4 
enzyme. Consistent with this ﬁ  nding is the absence of clini-
cally signiﬁ  cant drug interactions between rosuvastatin and 
other drugs known to inhibit CYP 450 enzymes.2,3
Safety, tolerability
The beneﬁ  ts of statins are well documented. However, 
lipid-lowering drugs may cause myopathy, even rhabdomy-
olysis, the risk of which is increased by certain interactions. 
Rosuvastatin is excreted mainly unchanged, and its plasma 
concentrations are not signiﬁ  cantly increased by cytochrome 
inhibitors.
Other clinically relevant intractions are nevertheless 
possible. Cyclosporine (INN, ciclosporin) inhibits CYP3A4, 
P-glycoprotein (multidrug resistance protein 1), organic anion 
transporting polypeptide 1B1 (OATP1B1), and some other 
hepatic uptake transporters. Gemﬁ  brozil and its glucuronide 
also inhibit OATP1B1. A genome-wide search demonstrated 
a strong association between myopathy with a single nucleo-
tide polymorphism located within SLCO1B1, which encodes 
OATP1B1.4 One common variant in SLCO1B1 is associated 
with increased risk of statin-induced myopathy. The effects 
of cyclosporine and gemﬁ  brozil, leading to inhibition of 
statin biliary excretion, explain the increased plasma statin 
concentrations and, together with pharmacodynamic factors, 
the increased risk of myotoxicity when coadministered with 
statins. In addition, inhibitors of hepatic uptake transporters 
may decrease the beneﬁ  t/risk ratio of statins by interfering 
with their entry into hepatocytes, their site of action.5–7
In particular, rosuvastatin exposure was signiﬁ  cantly 
increased in transplant recipients on antirejection regi-
men including cyclosporine. Cyclosporine inhibition of 
OATP-C-mediated rosuvastatin hepatic uptake may be the 
mechanism of this drug-drug interaction. Coadministration 
of rosuvastatin with cyclosporine needs to be undertaken 
with caution.8
A potential interaction between rosuvastatin and amio-
darone, leading to elevated serum transaminase levels, has 
been suggested.9
The safety and tolerability of rosuvastatin were assessed 
using data from 12,400 patients who had received 5 to 40 mg 
of rosuvastatin in a multinational phase II/III program, which 
represented 12,212 patient-years of continuous exposure to 
rosuvastatin. An integrated database was used to examine 
adverse events and laboratory data. In controlled clinical 
trials with comparator statins, 5 to 40 mg of rosuvastatin 
showed an adverse event proﬁ  le similar to those for 10 to 
80 mg of atorvastatin, 10 to 80 mg of simvastatin, and 10 to 
40 mg of pravastatin.
Clinically signiﬁ  cant elevations in alanine aminotrans-
ferase (3 times the upper limit of normal) and creatine 
kinase (CK) (10 times the upper limit of normal) were 
uncommon (0.2%) in the groups that received rosuvastatin 
and comparator statins. Myopathy (CK 10 times the upper 
limit of normal with muscle symptoms) possibly related to 
treatment occurred in approximately 0.03% of patients who 
took rosuvastatin at doses up to 40 mg. Incidence of protein-
uria during rosuvastatin treatment was comparable to that 
seen with other statins, and the development of proteinuria 
was not predictive of acute or progressive renal disease. No 
deaths in the program were attributed to rosuvastatin, nor did 
rhabdomyolysis occur in patients who received 5 to 40 mg 
of rosuvastatin.10
Myalgia, in the absence of CK elevation, is among the 
reasons leading patients to discontinue statins. Data from 
systematic reviews, meta-analyses, clinical and observational 
trials, and post-marketing surveillance indicate that statin-
associated myalgia affects approximately 5.0% of patients, 
as myopathy in 0.1% and as rhabdomyolysis in 0.01%. In 
the case of myalgia it is recommended that patients undergo: 
(1) creatine kinase measurements and monitoring; (2) statin 
dosage reduction, discontinuation, and rechallenge; and 
(3) alternate-day therapy.11
A retrospective study evaluated tendon manifestations in 
statin-treated patients. Data from 31 French Pharmacovigilance 
Centers from 1990 to 2005 included adverse effects involving 
patient’s tendons. Data were collected from 96 patients with 
tendon manifestations (median age of 56 years), namely ten-
donitis (n = 63) and tendon rupture (n = 33). Tendonopathy 
more often occurred within the ﬁ  rst year after statin initiation 
(59%). Tendon manifestations were related to rosuvastatin in 
ﬁ  ve cases. Statin was reinitiated in 7 patients receiving differ-
ent statin treatment, resulting in recurrence of tendonopathy 
in all cases. This patient series suggests that statin-attributed 
tendonous complications are relatively rare, considering the 
huge number of statin prescriptions. Prescribers should be 
aware of these complications related, particularly in risky 
situations, including physical exertion and association with 
medications known to increase the toxicity of statins.12
As with other statins, serious adverse effects with rosuv-
astatin therapy are uncommon and primarily involve effects 
on the liver and skeletal muscle. The risk increases with 
increasing dosages and coadministration with other drugs Vascular Health and Risk Management 2009:5 345
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interacting with the same metabolic pathway. In the case of 
less than adequate reduction in LDL cholesterol levels with 
statin therapy of moderate potency, the clinician can up-titrate 
the dose of the initial statin, switch to a combination therapy 
(for example, including ezetimibe) and carefully monitor for 
adverse effects, or start a lower dose of a more potent statin 
(rosuvastatin or atorvastatin). The decision is based on the 
degree of lipid lowering required and on safety, cost, and 
compliance considerations.13
Dose, titration, target
The degree of LDL reduction is important to achieve the 
treatment goals suggested by guidelines. The NCEP III 
recommends a goal of less than 100 mg dL for patients at 
high risk for coronary heart disease. In Europe, the Joint 
European Societies’ indicate a LDL cholesterol goal of less 
than 116 mg/dL. On the basis of available clinical trials, there 
is no evidence that achieving and maintaining such low levels 
of LDL cholesterol result in excess adverse effects. Among 
the most potent statins, rosuvastatin is capable of getting the 
majority of patients to their LDL cholesterol goals.14
Patients at very high risk for coronary artery disease 
beneﬁ  t from treatment that lowers LDL cholesterol plasma 
levels below 1.81 mmol/L (70 mg/dL) and the NCEP III 
recommendations were amended to incorporate this. 
To reach these more aggressive goals and plasma LDL 
cholesterol reductions, more aggressive therapies will be 
required. To implement more aggressive treatment there 
is indication to start with one of the more potent statins, 
especially rosuvastatin or atorvastatin. These more potent 
statins appear to be safe, even when used at higher doses. 
The incidence of myopathy and rhabdomyolysis, as docu-
mented in long-term clinical trials, is 0.1% and 0.01%, 
respectively.15
Rosuvastatin was introduced in the market more recently 
than other statins and most clinical trials used atorvastatin 
as the best available reference treatment. A double-blind, 
multicenter, randomized trial compared rosuvastatin 
and atorvastatin for reducing LDL cholesterol in adults 
with hypercholesterolemia and a high risk of coronary 
heart disease. At 24 weeks, LDL cholesterol was reduced 
significantly more with 80 mg rosuvastatin than with 
atorvastatin 80 mg (60% vs 52%). At 12 weeks, rosuvastatin 
10 mg reduced LDL cholesterol signiﬁ  cantly more than 
atorvastatin 10 mg (47% vs 35%). Therefore, more patients 
receiving rosuvastatin achieved LDL cholesterol goals and 
the effects of the two agents on triglycerides were similar.16 
A parallel decrease of the serum levels of non-high density 
lipoprotein (HDL) cholesterol and apolipoprotein-B has also 
been demonstrated.17After 6 week treatment of rosuvastatin 
at different dosages, non-HDL cholesterol was reduced in 
the range of 42% to 51% and apolipoprotein-B in the range 
of 37% to 45%. A treatment target of 90 mg/dL has been 
proposed for apolipoprotein-B.18
A multinational trial on hypercholesterolemic patients 
(n = 3140) with coronary heart disease, atherosclerosis, 
or type 2 diabetes assessed the effects of switching to low 
doses of rosuvastatin from commonly used doses of ator-
vastatin, simvastatin, and pravastatin on LDL cholesterol 
goal achievement in high-risk patients. The primary efﬁ  cacy 
measure was the proportion of patients reaching the Joint 
European Societies’ LDL cholesterol goal (116 mg/dL) 
at week 16. Signiﬁ  cant improvement in LDL cholesterol 
goal achievement was found for patients who switched to 
rosuvastatin 10 mg, compared with those who remained on 
atorvastatin 10 mg (86% vs 80%), simvastatin 20 mg (86% 
vs 72%), and pravastatin 40 mg (88% vs 66%), and between 
patients switched to rosuvastatin 20 mg and those who 
remained on atorvastatin 20 mg (90% vs 84%). Similar results 
were found for achievement of the European combined LDL 
cholesterol and total cholesterol goals and NCEP III LDL 
cholesterol goals.19
Rosuvastatin was tested in patients with severe hypercholes-
terolemia who are relatively refractory to lipid-lowering treat-
ment. Heterozygous familial hypercholesterolemia (HFH) is a 
genetic disorder, associated with severe hypercholesterolemia 
and increased risk of early coronary artery disease. A study 
compared atorvastatin and rosuvastatin in reducing LDL 
cholesterol in HFH: 623 patients were randomized to 
20 mg/day of atorvastatin (n = 187) or rosuvastatin (n = 436) 
with forced titration at 6-week intervals to 80 mg/day. At 
week 18, rosuvastatin therapy produced a greater reduction 
in LDL cholesterol (−57.9% vs −50.4%; p  0.001) and a 
greater increase in HDL cholesterol (12.4% vs 2.9%) than 
atorvastatin. Rosuvastatin also produced signiﬁ  cantly greater 
reductions in apolipoprotein-B, as well as a signiﬁ  cantly 
greater increase in apolipoprotein A-I. More patients with 
HFH and coronary artery disease achieved the NCEP III goal 
of LDL cholesterol 100 mg/dL (2.6 mmol/L) on rosuvas-
tatin 40 and 80 mg than atorvastatin 80 mg (17%, 24%, and 
4.5%, respectively). High-sensitivity C-reactive protein (CRP) 
median values were reduced by 33% to 34% in both the 80-mg 
rosuvastatin- and atorvastatin-treated groups.20
Another multicenter study assessed efﬁ  cacy and safety 
of a ﬁ  xed dose of rosuvastatin (40 mg) in 1380 patients with 
severe hypercholesterolemia, including HFH. Adult patients Vascular Health and Risk Management 2009:5 346
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with fasting LDL cholesterol between 190 and 260 mg/dL and 
triglycerides below 400 mg/dL received rosuvastatin 40 mg 
for 48 to 96 weeks. At 12 weeks, 83% of patients achieved 
NCEP ATP III LDL cholesterol goals, which were main-
tained during 2 to 4 years. At 4 years, LDL cholesterol was 
reduced by 54% and HDL cholesterol increased by 13%.21
As shown previously, rosuvastatin produces favorable 
effects on HDL cholesterol, which is an independent marker 
of cardiovascular risk. This has been evaluated in patients with 
the metabolic syndrome (MS), a constellation of coronary risk 
factors, including low HDL cholesterol. A post hoc analysis 
of data from a 6-week, randomized, open-label, parallel-
group, comparative trial (Statin Therapies for Elevated Lipid 
Levels compared Across doses to Rosuvastatin [STELLAR]) 
assessed the effects of rosuvastatin and atorvastatin on plasma 
lipids in hypercholesterolemic patients (LDL cholesterol 
between 160 and 250 mg/dl; triglycerides below 400 mg/dL) 
who had at least 3 of the 5 of the NCEP III criteria for MS. 
Of 2268 patients, 811 met criteria for MS. Percent reductions 
in LDL cholesterol were of 55% in the rosuvastatin 40-mg 
group. In patients with MS, triglyceride reductions ranged 
from 22% to 34% with rosuvastatin, and from 23% to 33% 
with atorvastatin. HDL cholesterol increased by 8% to 11% 
with rosuvastatin, and 5% to 9% with atorvastatin.22
The mechanism by which rosuvastatin increases 
HDL cholesterol is unclear. To clarify this, 12 men with 
the metabolic syndrome were studied in a randomized, 
double-blind, crossover trial of 5-week therapeutic periods 
with placebo, 10 mg/day rosuvastatin, or 40 mg/day 
rosuvastatin, with 2-week placebo washout between 
each period. Compared with placebo, there was a signiﬁ  cant 
dose-dependent increase in HDL cholesterol, HDL particle 
size, and concentration of HDL particles containing 
apolipoprotein-I. The increase in apolipoprotein-I 
concentration was associated with significant dose-
dependent reductions in triglyceride concentration and 
apolipoprotein-I fractional catabolic rate, with no changes 
in apolipoprotein-I production rate. There was a signiﬁ  cant 
dose-dependent reduction in the fractional catabolic rate 
of HDL particles containing both apolipoprotein A-I and 
A-II, with a concomitant reduction in apolipoprotein-I:
apolipoprotein-II production rate, and hence no change in 
apolipoprotein-I:apolipoprotein-II concentration. Thus, 
Rosuvastatin dose-dependently increased plasma HDL 
cholesterol and apolipoprotein-I concentrations in the 
metabolic syndrome. This could relate to the reduction in 
plasma triglycerides with remodeling of HDL particles and 
reduction in apolipoprotein-I fractional catabolism.23
Another study compared the effects of daily doses of 
rosuvastatin 40 mg with atorvastatin 80 mg during a 6-week 
period on HDL subpopulations in 306 hyperlipidemic men and 
women. Other studies had previously shown that increased 
levels of large alpha-1 and alpha-2 HDLs decrease the risk 
of coronary heart disease and protect against progression of 
coronary atherosclerosis. In this study, both statins caused 
signiﬁ  cant increases in large alpha-1 and decreases in small 
pre-beta-1 HDL levels; however, increases in the 2 large 
HDL particles were higher for rosuvastatin than atorvastatin 
(alpha-1, 24% vs 12%; alpha-2, 13% vs 4%). Statin-induced 
increases in alpha-1 and alpha-2 correlated with increases 
in HDL cholesterol, whereas decreases in pre-beta-1 were 
associated with decreases in triglycerides. In subjects with 
low HDL cholesterol (40 mg/dL for men, 50 mg/dL for 
women, n = 99), increases in alpha-1 were 32% vs 11%, 
and in alpha-2, 21% vs 5% for rosuvastatin and atorvastatin, 
respectively. Therefore, both statins, given at their maximal 
doses, favorably alter the HDL subpopulation proﬁ  le, with 
rosuvastatin being more effective than atorvastatin.24
The effects of rosuvastatin on triglyceride rich lipo-
proteins and HDL were evaluated in patients with com-
bined dyslipidemia and insulin resistance, before and after 
3 months’ treatment with gemﬁ  brozil (1200 mg/day) or 
rosuvastatin (40 mg/day) with regard to: (1) steady-state 
plasma glucose concentration at the end of a 180-minute 
infusion of octreotide, insulin, and glucose; (2) fasting lipid, 
lipoprotein, and apolipoprotein concentrations; and (3) day-
long glucose, insulin, triglyceride, and remnant lipoprotein 
cholesterol concentrations in response to breakfast and lunch. 
The two groups were similar at baseline in terms of age, 
gender, body mass index and measurements of carbohydrate 
and lipoprotein metabolism. Neither gemﬁ  brozil nor rosuv-
astatin enhanced insulin sensitivity or lowered day-long glu-
cose and insulin concentrations in insulin-resistant patients 
with combined dyslipidemia, but both drugs signiﬁ  cantly 
decreased fasting triglyceride concentrations. Only rosuvas-
tatin treatment signiﬁ  cantly reduced fasting LDL cholesterol, 
apolipoprotein B-100, apolipoprotein C-III, apolipoprotein 
C-III:B particles, the apolipoprotein B-100:apolipoprotein 
A-I ratio, and increased apolipoprotein A-I. The degree of 
improvement in fasting and postprandial remnant lipoprotein 
cholesterol concentrations was relatively greater (p  0.05) 
in rosuvastatin-treated patients.25
Small dense LDL (sdLDL) is a highly atherogenic 
sub-fraction of LDL, which is often increased in hyper-
triglyceridemic patients. In a post hoc sub-analysis of an 
open-label study, the effect of daily oral doses of rosuvastatin Vascular Health and Risk Management 2009:5 347
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40 mg and atorvastatin 80 mg on sdLDL cholesterol were 
compared, over a 6-week period in 271 hyperlipidemic 
patients. Rosuvastatin was (p  0.01) more effective than 
atorvastatin in decreasing sdLDL cholesterol (−53% vs 
−46%), the two statins caused similar decreases in triglyc-
eride levels (−24% and −26%).26
In general, statins decrease CRP in addition to LDL 
cholesterol, which may further decrease coronary heart disease 
risk. Rosuvastatin was compared with atorvastatin in achiev-
ing a combined target of LDL cholesterol 70 mg/dL and 
CRP 2 mg/L in 509 patients with type 2 diabetes mellitus. 
CRP decreased vs baseline in both treatment groups. More 
patients treated with rosuvastatin achieved the combined end 
point of LDL cholesterol 70 mg/dL and CRP 2 mg/L 
compared with atorvastatin by the end of the study period 
(58% vs 37%; p  0.001 vs atorvastatin). In conclusion, CRP 
was effectively reduced in patients with type 2 diabetes receiv-
ing rosuvastatin or atorvastatin, whereas rosuvastatin decreased 
LDL cholesterol relatively more than atorvastatin.27
The use of statins is associated with reduced thrombosis 
burden and diminished platelet activity, as shown in animal 
models and in vitro studies. Seventy patients with the meta-
bolic syndrome who were not taking antiplatelet agents were 
consecutively assigned to one of six statins (atorvastatin, 
ﬂ  uvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin) 
at starting doses or to a no-statin group, at the discretion of the 
responsible clinician, for a period of 6 weeks. Rosuvastatin 
and the other statins inhibited the activity and antigen level of 
the platelet PAR-1 thrombin receptor, which has a major role 
in regulating platelet activity and thrombin formation.28
In managed care, patients at high risk for coronary heart 
disease participated in a randomized, open-label, multicenter 
trial (SOLAR [Satisfying Optimal LDL-C ATP III goals with 
Rosuvastatin]), which was performed at 145 US clinical cen-
ters. High-risk men and women in a managed care population 
received typical starting doses of rosuvastatin (10 mg/day), 
atorvastatin (10 mg/day), or simvastatin (20 mg/day) for 
6 weeks. Those who did not meet the LDL-C target of less 
than 100 mg/dL at 6 weeks had their dose titrated (doubled), 
and all patients were followed up for another 6 weeks. 
A total of 1632 patients were randomized to one of the three 
treatment regimens. After 12 weeks, 76% of patients taking 
rosuvastatin reached the LDL-C target of less than 100 mg/dL 
vs 58% with atorvastatin and 53% with simvastatin. Adverse 
events were similar for type and frequency in all treatment 
groups, and only 3% of all patients discontinued treatment 
because of adverse events. No myopathy was observed, no 
clinically important impact on renal function was attributed 
to study medications, and clinically important increases in 
serum transaminases were rare.29
Statin therapy decreases LDL cholesterol levels and 
the risk of coronary heart disease but has a considerable 
short-term effect on health care budgets. In the US, the cost 
effectiveness of rosuvastatin has been compared with those 
of atorvastatin, pravastatin, and simvastatin in lowering LDL 
cholesterol levels and achieving NCEP III LDL cholesterol 
goals. Clinical data were obtained from the Statin Thera-
pies for Elevated Lipid Levels Compared Across Doses to 
Rosuvastatin (STELLAR) trial. Drug costs were based on 
wholesale acquisition costs. Cost effectiveness was assessed 
with the net monetary beneﬁ  t approach and a 1-year time 
horizon. Rosuvastatin was demonstrated to be the most 
cost-effective statin.30
The new target (LDL cholesterol below 70 mg/dL) indi-
cated by the NCEP III guidelines for patients at high risk of 
coronary heart disease can be difﬁ  cult to attain with diet and 
current therapy. In a 16-week multinational trial, 1993 high-risk 
patients were randomized to rosuvastatin 20 mg, atorvastatin 
10 mg, atorvastatin 20 mg, simvastatin 20 mg, or simvastatin 
40 mg for 8 weeks. Patients either remained on starting treat-
ment or switched to lower or milligram-equivalent doses of 
rosuvastatin for 8 more weeks. More very high risk patients 
achieved an LDL-C target of 70 mg/dL when changed to 
rosuvastatin from atorvastatin or simvastatin.31
Patients at risk of coronary heart disease may not achieve 
recommended LDL cholesterol goals on statin monotherapy. 
A study was designed to investigate the efﬁ  cacy and safety of 
rosuvastatin 40 mg alone or in combination with ezetimibe 
10 mg in patients at high risk of coronary heart disease. 
Four hundred sixty-nine patients were randomly assigned 
to rosuvastatin alone or in combination with ezetimibe for 
6 weeks. Signiﬁ  cantly more patients receiving rosuvastatin/
ezetimibe than rosuvastatin alone achieved their ATP III 
LDL cholesterol goal (100 mg/dL, 94.0% vs 79.1%) and 
the optional LDL cholesterol goal (70 mg/dL) for very 
high-risk patients (79.6% vs 35.0%). The combination of 
rosuvastatin/ezetimibe reduced LDL cholesterol signiﬁ  cantly 
more than rosuvastatin (−69.8% vs −57.1%).32
Vascular trials
Atherosclerosis is often at an advanced stage when symp-
toms appear: vascular abnormalities are detectable before 
overt clinical disease and stabilization of vulnerable plaque 
is thought to precede reduction in cardiovascular events. 
Vascular end-points have thus been used to evaluate the 
impact of lipid-lowering treatment on the vascular system. Vascular Health and Risk Management 2009:5 348
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Also in the case of rosuvastatin, controlled clinical trials 
using vascular end-points have been performed.
A study assessed whether statin therapy could slow 
progression and/or cause regression of carotid intima-media 
thickness (CIMT) over 2 years in middle-aged individuals 
with a low Framingham risk score (FRS) and mild to moder-
ate subclinical atherosclerosis. This randomized, double-blind, 
placebo-controlled study (Measuring Effects on Intima-Media 
Thickness: an Evaluation of Rosuvastatin [METEOR]) of 984 
individuals, with either age (mean, 57 years) as the only coro-
nary heart disease risk factor or a 10-year FRS of less than 10%, 
modest CIMT thickening (1.2–3.5 mm), and elevated LDL cho-
lesterol (mean, 154 mg/dL), was conducted in 61 primary care 
centers in the United States and Europe. Participants received 
either a 40-mg dose of rosuvastatin or placebo.
Rate of change in CIMT was assessed by B-mode ultrasound 
for 12 carotid sites, at the level of the common carotid artery, 
carotid bulb, and internal carotid artery. Among participants 
in the rosuvastatin group, the mean baseline LDL cholesterol 
level of 155 mg/dL declined to 78 mg/dL, with a mean reduc-
tion of 49%. The change in maximum CIMT for the 12 carotid 
sites was −0.0014 mm per year for the rosuvastatin group 
vs +0.0131 mm per year for the placebo group (p  0.001). In 
summary, middle-aged adults with an FRS of less than 10% 
and evidence of subclinical atherosclerosis, taking rosuvastatin, 
experienced signiﬁ  cant reductions in the rate of progression of 
maximum CIMT over 2 years vs placebo.33
To further evaluate the impact of rosuvastatin treatment on 
carotid atherosclerosis, magnetic resonance imaging (MRI) 
was used to non-invasively assess changes in atherosclerotic 
plaque morphology and composition (ORION trial). The 
randomized, double-blind ORION trial used 1.5-T MRI to 
image carotid atherosclerotic plaques at baseline and after 
24 months of rosuvastatin treatment. Forty-three patients 
with fasting LDL cholesterol between 100 and 250 mg/dL 
and 16% to 79% carotid stenosis by duplex ultrasound were 
randomized to receive either a low (5 mg) or high (40/80 mg) 
dose of rosuvastatin. In these patients with moderate hyper-
cholesterolemia, rosuvastatin treatment was associated with 
a reduction in percent of lipid-rich necrotic core, whereas the 
overall plaque burden remained unchanged over the course 
of 2 years of treatment.34 The results of this study and of the 
previous one support the idea that long term treatment with 
rosuvastatin stabilizes carotid plaques.
Prior intravascular ultrasound (IVUS) trials have demon-
strated slowing or halting of atherosclerosis progression with 
statin therapy but have not provided convincing evidence of 
regression using percent atheroma volume, the most rigorous 
IVUS measure of disease progression and regression. 
To assess whether very intensive statin therapy could induce 
regression of coronary atherosclerosis, a prospective, open-
label blinded end-points trial (A Study to Evaluate the Effect 
of Rosuvastatin on Intravascular Ultrasound-Derived Coro-
nary Atheroma Burden [ASTEROID]) was performed at 53 
community and tertiary care centers in the United States, 
Canada, Europe, and Australia.
After 24 months, 349 patients had evaluable serial 
IVUS examinations. Very high-intensity statin therapy 
using rosuvastatin 40 mg/day achieved an average LDL-C 
of 60.8 mg/dL and increased HDL-C by 14.7%, resulting in 
signiﬁ  cant regression of atherosclerosis for all prespeciﬁ  ed 
IVUS measures of disease burden.35
In the same study, blinded quantitative coronary angiog-
raphy analyses of percent diameter stenosis and minimum 
lumen diameter were performed for up to 10 segments of 
coronary arteries and major branches with 25% diameter 
stenosis at baseline. For each patient, the mean of all matched 
lesions at baseline and study end was calculated. There were 
292 patients with 613 matched stenoses.
Rosuvastatin treatment for 24 months to average LDL 
cholesterol levels well below 70 mg/dL, accompanied by 
signiﬁ  cant increases in HDL cholesterol, produced regression 
by decreasing percent diameter stenosis and improving mini-
mum lumen diameter as measured by quantitative coronary 
angiography in coronary disease patients.36
On-trial effect of rosuvastatin on glomerular ﬁ  ltration rate 
(GFR) can be regarded as evidence of therapeutic impact on 
a micro-vascular end-point.
To better deﬁ  ne the effect of short-term rosuvastatin 
treatment on the estimated glomerular ﬁ  ltration rate (eGFR), 
the database of controlled clinical trials in the Rosuvastatin 
Clinical Development Program was reviewed. Thirteen studies 
comprising 3956 rosuvastatin-treated patients were selected 
based on a serum creatinine measurement at 6 or 8 weeks 
after initiation of rosuvastatin treatment, randomization to 
approved and marketed rosuvastatin doses (5 to 40 mg), and 
unchanged rosuvastatin dose from treatment initiation (base-
line) through 6 to 8 weeks of treatment. eGFR was determined 
with the Modiﬁ  cation of Diet in Renal Disease formula. eGFR 
signiﬁ  cantly increased for each dose of rosuvastatin individu-
ally and for all doses combined compared to baseline (range 
+0.9 to +3.2 mL/min/1.73 m2). Further analysis of 5 blinded, 
placebo-controlled trials comprising 525 patients showed an 
increase in eGFR of +0.8 mL/min/1.73 m2 for all rosuvastatin-
treated patients, which was signiﬁ  cantly different from a 
change of −1.5 mL/min/1.73 m2 in the placebo-treated patients. Vascular Health and Risk Management 2009:5 349
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The increase in eGFR for rosuvastatin-treated patients was 
consistent across all major demographic and clinical sub-
groups of interest, including patients with baseline proteinuria, 
baseline eGFR 60 mL/min/1.73 m2, and in patients with 
hypertension and/or diabetes. In conclusion, these results are 
consistent with previous rosuvastatin studies that showed an 
upward trend in eGFR with long-term treatment.37
One possible mechanism underlying the favorable vas-
cular effect of rosuvastatin treatment focuses on improve-
ment of endothelial dysfunction. Elevated plasma levels of 
asymmetric dimethylarginine (ADMA) have been associated 
with attenuated endothelium-dependent vasodilation in 
hypercholesterolemic patients. A multicenter, randomized, 
double-blind, placebo-controlled study included 46 patients 
with elevated LDL cholesterol. Patients were randomized 
into 2 groups: rosuvastatin 10 mg/day and placebo for 
6 weeks. Plasma levels of ADMA, 8-isoprostane (as a marker 
of oxidative stress), homocysteine, and high-sensitivity CRP 
were measured at baseline and 6 weeks later.
Endothelial function assessed by ﬂ  ow-mediated vaso-
dilation of the brachial artery was performed in 11 patients 
in the rosuvastatin group and in 12 in the placebo group. 
Baseline characteristics of both groups were similar, and 
the plasma ADMA levels were significantly correlated 
with 8-isoprostane. After 6 weeks of treatment, plasma 
ADMA levels were signiﬁ  cantly reduced in the rosuvastatin 
group (from 0.60 to 0.49 μmol/L, p  0.001). Increases 
in ﬂ  ow-mediated vasodilation were positively correlated 
with reductions in plasma levels of ADMA and LDL cho-
lesterol. Thus, these ﬁ  ndings suggest that treatment with 
rosuvastatin in patients with hypercholesterolemia may lead 
to a signiﬁ  cant reduction in plasma ADMA levels, which 
appear to be related to the improvement in endothelial func-
tion by rosuvastatin.38
Secondary prevention
There are overwhelming data in favor of cholesterol as a 
modiﬁ  able risk factor for clinically overt coronary artery 
disease. In this area, rosuvastatin trials are showing their 
ﬁ  rst, although promising results.39
Patients with acute coronary syndrome (ACS) were 
randomly assigned, before percutaneous coronary interven-
tion (PCI), to either the group of no statin treatment (control 
group: n = 220, 63 years, male 62%) or the group of 40 mg 
rosuvastatin loading before PCI (rosuvastatin group: n = 225, 
64 years, male 60%). Incidence of periprocedural myocardial 
injury was assessed by analysis of CK-MB and cardiac 
troponin T before PCI, at 6 hours and the next morning 
after PCI. After PCI, incidence of periprocedural myocardial 
injury was higher in controls than in the rosuvastatin group 
(11.4% vs 5.8%). Mean preprocedural CK-MB and high sen-
sitivity CRP were similar between the two groups, whereas 
after PCI, peak values of both markers were signiﬁ  cantly 
higher in controls than in the rosuvastatin group. Multivari-
ate analysis revealed that no prior use of statin, procedural 
complication and multi-vessel disease were the independent 
predictors for periprocedural myocardial infarction. Thus, a 
single high dose of rosuvastatin prior to PCI reduces peripro-
cedural myocardial injury in patients with ACS.40
Primary prevention
Considering the limitations of current risk assessment strate-
gies, adjunctive markers are needed to improve the predic-
tion of a ﬁ  rst coronary event. Research on the inﬂ  ammatory 
nature of atherosclerosis suggests that inﬂ  ammatory-response 
proteins may serve as potential predictors of clinical events. 
One in particular, CRP, has been the focus of much attention. 
Epidemiologic studies have shown a fairly consistent inde-
pendent association between high-sensitivity CRP (hs-CRP) 
elevations and coronary risk, although a causal relation has 
not yet been established.41,42
JUPITER43 is a randomized, double-blind, placebo-
controlled primary prevention trial of statin therapy among 
persons with average to low levels of LDL cholesterol who 
are at increased cardiovascular risk due to elevated plasma 
concentrations of the inflammatory biomarker hs-CRP. 
A total of 17,802 individuals with LDL cholesterol less 
than 130 mg/dL (3.36 mmol/L) and hs-CRP above 2 mg/L 
were recruited from 26 countries and randomly allocated to 
20 mg/day rosuvastatin or placebo. In contrast to previous 
studies of statin therapy in primary prevention, JUPITER 
evaluated a group with modest plasma concentrations of 
LDL cholesterol (median 108 mg/dL). Further, the trial 
included 6801 women (38.2%) and 5577 individuals with 
metabolic syndrome (32.1%). Most participating patients 
were overweight or frankly obese.
On March 31, 2008 the decision was announced to stop 
the JUPITER clinical study early based on a recommendation 
from an Independent Data Monitoring Board and the JUPITER 
Steering Committee, which met on March 29, 2008. The study 
was stopped early (after a median follow-up of approximately 
2 years) because there was unequivocal evidence of a reduction 
in cardiovascular morbidity and mortality among patients who 
received rosuvastatin when compared to placebo.
Recently the final data of this study have become 
available.44 Rosuvastatin reduced LDL cholesterol levels Vascular Health and Risk Management 2009:5 350
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by 50% and hs-CRP levels by 37%. The rates of the primary 
end point (combined primary end point of myocardial 
infarction, stroke, arterial revascularization, hospitalization 
for unstable angina, or death from cardiovascular causes) 
were 0.77 and 1.36 per 100 person-years of follow-up in the 
rosuvastatin and placebo groups, respectively (hazard ratio 
for rosuvastatin, 0.56; p  0.00001), with corresponding 
rates of 0.17 and 0.37 for myocardial infarction (hazard ratio, 
0.46; p = 0.0002), 0.18 and 0.34 for stroke (hazard ratio, 0.52; 
p = 0.002), 0.41 and 0.77 for revascularization or unstable 
angina (hazard ratio, 0.53; p  0.00001), 0.45 and 0.85 for the 
combined end point of myocardial infarction, stroke, or death 
from cardiovascular causes (hazard ratio, 0.53; p  0.00001), 
and 1.00 and 1.25 for death from any cause (hazard ratio, 0.80; 
p = 0.02). The rosuvastatin group did not have a signiﬁ  cant 
increase in myopathy or cancer but did have a higher incidence 
of physician-reported diabetes. In this primary prevention trial 
on persons without hyperlipidemia but with elevated hs-CRP 
levels, rosuvastatin signiﬁ  cantly reduced the incidence of 
major cardiovascular events.
Conclusion/expert comment
On the basis of the above data, it can be concluded that 
rosuvastatin beneﬁ  cially alters the entire spectrum of lipo-
protein particles.
Results of previous randomized trials have shown that 
interventions able to lower LDL cholesterol concentrations 
can signiﬁ  cantly reduce the incidence of coronary heart 
disease and other major vascular events in a wide range of 
individuals. However, each separate trial has limited power 
to assess speciﬁ  c outcomes or categories of participants. 
A prospective meta-analysis of data from 90,056 individuals 
in 14 randomized trials of statins was carried out. Weighted 
estimates were obtained of the effects on different clinical 
outcomes per 1.0 mmol/L reduction in LDL cholesterol. Over 
a mean period of 5 years, 8186 people died, 14,348 had major 
vascular events, and 5103 developed cancer. Mean LDL 
cholesterol differences at 1 year ranged from 0.35 mmol/L 
to 1.77 mmol/L (mean 1.09) in these trials. There was a 12% 
proportional reduction in all-cause mortality per mmol/L 
reduction in LDL cholesterol. This reﬂ  ected a 19% reduc-
tion in coronary mortality, and non-signiﬁ  cant reductions in 
non-coronary vascular mortality. There were corresponding 
reductions in myocardial infarction or coronary death, in the 
need for coronary revascularisation, and in fatal or non-fatal 
stroke; combining these, there was a 21% decrease in any 
such major vascular event. These beneﬁ  ts were signiﬁ  cant 
within the ﬁ  rst year, but were greater in subsequent years. 
There was no evidence that statins increased the incidence 
of cancer overall or at any particular site.
The proportional reduction in major vascular events 
differed signiﬁ  cantly according to the absolute reduction in 
LDL cholesterol achieved. Prolonged rosuvastatin treatment, 
which is associated with substantial LDL cholesterol lower-
ing, is expected to produce pronounced beneﬁ  t in all patients 
at high risk of any type of major vascular event.45
To determine the extent to which statins reduce serum 
concentrations of LDL cholesterol and incidence of ischemic 
heart disease (IHD) events and stroke, according to drug, 
dose, and duration of treatment, 3 meta-analyses were 
performed: 164 short term randomized placebo controlled 
trials of 6 statins and LDL cholesterol reduction; 58 ran-
domized trials of cholesterol lowering by any means and 
IHD events; and 9 cohort studies and the same 58 trials on 
stoke. Reductions in LDL cholesterol according to statin and 
dose and reduction in IHD events and stroke for a speciﬁ  ed 
reduction in LDL cholesterol were calculated. Reductions 
in LDL cholesterol (in the 164 trials) were 2.8 mmol/L 
(60%) with rosuvastatin 80 mg/day, 2.6 mmol/L (55%) with 
atorvastatin 80 mg/day, 1.8 mmol/L (40%) with atorvastatin 
10 mg/day, lovastatin 40 mg/day, simvastatin 40 mg/day, or 
rosuvastatin 5 mg/day, all from pretreatment concentrations 
of 4.8 mmol/L. Pravastatin and ﬂ  uvastatin achieved smaller 
reductions. In the 58 trials, for an LDL cholesterol reduction 
of 1.0 mmol/L the risk of IHD events was reduced by 11% 
in the ﬁ  rst year of treatment, 24% in the second year, 33% 
in 3 to 5 years, and by 36% thereafter (p  0.001 for trend). 
IHD events were reduced by 20%, 31%, and 51% in trials 
grouped by LDL cholesterol reduction (means 0.5 mmol/L, 
1.0 mmol/L, and 1.6 mmol/L). After several years a reduc-
tion of 1.8 mmol/L should reduce IHD events by an esti-
mated 61%. Results from the same 58 trials, corroborated 
by results from the nine cohort studies, show that lowering 
LDL cholesterol decreases all stroke events by 10% for a 
1 mmol/L reduction and by 17% for a 1.8 mmol/L reduction. 
Rosuvastatin, at its lowest dose (5 mg/day) can lower LDL 
cholesterol concentration by an average of 1.8 mmol/L which 
reduces the risk of IHD events by about 60% and stroke by 
17%. Even better results are expected after treatment at the 
commonly used dose of 10 mg/day.46
A prospective meta-analysis was performed on data 
from 18,686 individuals with diabetes (1466 with type 1 
and 17,220 with type 2), within the context of a further 
sample of 71,370 without diabetes in 14 randomized trials 
of statin therapy. Weighted estimates of the effects on clini-
cal outcomes per 1.0 mmol/L reduction in LDL cholesterol Vascular Health and Risk Management 2009:5 351
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were obtained. During a mean follow-up of 4.3 years, there 
were 3247 major vascular events in people with diabetes. 
There was a 9% proportional reduction in all-cause mortality 
per mmol/L reduction in LDL cholesterol in participants with 
diabetes, which was similar to the 13% reduction in those 
without diabetes. This ﬁ  nding reﬂ  ected a signiﬁ  cant reduction 
in vascular mortality and no effect on non-vascular mortality 
in participants with diabetes. There was a signiﬁ  cant 21% 
proportional reduction in major vascular events per mmol/L 
reduction in LDL cholesterol in people with diabetes, which 
was similar to the effect observed in those without diabetes. 
Rosuvastatin (10 mg/day) produces an average reduction of 
LDL cholesterol above 2.0 mmol/L. Therefore in the case 
of diabetic individuals who are at sufﬁ  ciently high risk of 
vascular events, a reduction of vascular events greater than 
50% is expected after long-term rosuvastatin treatment.47
Early epidemiological studies have identiﬁ  ed low levels 
of HDL cholesterol (1.0 mmol/L or 40 mg/dL), a common 
feature of type 2 diabetes mellitus and the metabolic syn-
drome, to be an independent determinant of increased car-
diovascular risk. The beneﬁ  cial effects of HDL cholesterol 
on the cardiovascular system have been attributed to its 
ability to remove cellular cholesterol, as well as its anti-
inﬂ  ammatory, antioxidant and antithrombotic properties, 
which act in concert to improve endothelial function and 
inhibit atherosclerosis, thereby reducing cardiovascular risk. 
As such, raising HDL cholesterol in patients with aggres-
sively lowered LDL cholesterol provides an additional 
strategy for addressing the residual cardiovascular risk pres-
ent in these patients groups. Studies suggest that for every 
0.03 mmol/L (1.0 mg/dL) increase in HDL cholesterol, 
absolute cardiovascular risk is reduced by 2% to 3%, in a 
4-year follow-up. Raising HDL cholesterol can be achieved 
by both lifestyle changes and pharmacological means, the 
former comprising mainly smoking cessation, aerobic 
exercise, weight loss and dietary manipulation. Therapeu-
tic strategies to increase HDL cholesterol include niacin, 
ﬁ  brates, thiazolidinediones and bile acid sequestrants.48
Rosuvastatin, which produces an increase in HDL choles-
terol in the range of 4 to 6 mg/dL, is expected, through this 
mechanism, to be responsible for an additional cardiovascular 
risk reduction in the range of 8% to 6%. Support for these new 
data come from the JUPITER study, which was stopped before 
the programmed end of the study because of excess beneﬁ  t for 
high-risk individuals receiving rosuvastatin treatment.40 It is 
suggested that pronounced LDL reduction, in association with 
signiﬁ  cant HDL cholesterol increase, are the bases of a marked 
preventive action of rosuvastatin. The results from JUPITER 
support the use of rosuvastatin for primary cardiovascular 
prevention, in overweight men and women, with near to nor-
mal LDL cholesterol and high CRP. There is now evidence 
of beneﬁ  t from rosuvastatin treatment for a wide segment of 
the general population at intermediate cardiovascular risk. In 
absolute numbers, this segment represents the main source of 
cardiovascular events.49 On the basis of JUPITER results, it 
is expected that treatment target and potential candidates for 
statin therapy will be revaluated and redeﬁ  ned.
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